SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Spero Therapeutics entered into a new at-the-market (ATM) equity…

Spero Therapeutics, Inc. · 8-K filed Aug 28, 2026 at 17:25 ET

At the news

BEARISHIMPACT 7/10

8-K filed Aug 28, 2026 at 17:25 ET

Spero Therapeutics entered into a new at-the-market (ATM) equity offering agreement with Jefferies LLC for up to $100M in common stock, filed concurrently with a $300M universal shelf registration statement (S-3). The company also terminated its prior $75M Cantor Fitzgerald ATM facility, under which it had sold no shares in FY2025 or FY2024. The new ATM is 1.4x the company's $70M market cap, representing massive potential dilution for a clinical-stage biotech with no approved products or near-term revenue prospects, and the shelf registration was filed just 16 days after a 10-Q showing a $70M market cap, signaling a distressed capital raise to fund preclinical development of SP001.

  • Entered into Open Market Sale Agreement with Jefferies LLC for up to $100M in common stock ATM offering.
  • Filed universal shelf registration statement (S-3) for up to $300M in securities, not yet effective.
  • Terminated prior Cantor Fitzgerald ATM facility ($75M capacity) effective August 28, 2026; no shares sold under that facility in FY2025 or FY2024.
  • The $100M ATM is approximately 1.4x the company's $70M market cap, indicating severe dilution risk.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access